The dermatology-focused biopharma firm reports a 17% year-over-year increase in product revenue for Q1 2026.
Biofrontera Inc. posted Q1 2026 product revenues of $10.1 million, up 17% from $8.6 million in the same period last year. The company highlighted strong performance across key metrics during its earnings call.
Management attributed the growth to expanded market penetration and higher demand for its dermatological treatments. The prior-year quarter had served as a baseline for the company’s turnaround strategy.
Biofrontera also reiterated its target of achieving cash flow breakeven in 2026 while maintaining gross margins of 80%-85%.